Skip to content

Impact of Telecoaching Program on Physical Activity in Patients With COPD

A 3-month Multicenter Randomized Trial to Evaluate the Efficacy of a Physical Activity Promotion Program on the Experience of Physical Activity in Patients With COPD (Mr PAPP)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02158065
Acronym
MrPAPP
Enrollment
370
Registered
2014-06-06
Start date
2014-05-31
Completion date
2015-03-31
Last updated
2015-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Keywords

Chronic obstructive pulmonary disease (COPD), physical activity, PROactive, telecoaching

Brief summary

The purpose of this 3 month randomized intervention study is to investigate the additional effect of a physical activity telecoaching program on physical activity in patients with COPD, compared with usual care.

Detailed description

In this 3 month, randomized (1:1 ratio), parallel-group, multicenter trial, patients in both groups (control and coaching) will receive information and guidance on the benefits associated with increased physical activity in COPD patients and their health status. Patients in both groups will use two PROactive monitors (ActiGraph® and DynaPort®) and a PDA to complete the PROactive questionnaire. In addition to above, the patients in the coaching group will receive daily coaching by a semiautomated system and coaching by the investigator during study visits.

Interventions

The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.

Sponsors

University of Edinburgh
CollaboratorOTHER
Royal Brompton & Harefield NHS Foundation Trust
CollaboratorOTHER
University Medical Center Groningen
CollaboratorOTHER
University of Athens
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
Barcelona Institute for Global Health
CollaboratorOTHER
KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent must be obtained before any assessment is performed * Male and female patients ≥ 40 years of age * Diagnosis of COPD (GOLD criteria: post bronchodilator FEV1/FVC\< 70%) * Current or ex-smokers with a smoking history equivalent to at least 10 pack years * Patient should have at least 4 days of physical activity data recorded via PROactive monitors during 7 days prior to the baseline measurement

Exclusion criteria

* Orthopedic, neurological or other complaints that significantly impair normal biomechanical movement patterns, as judged by the investigator. Specifically if the patients' condition/ co-morbidities are such that physical activity cannot be increased, then they should not be enrolled * Respiratory diseases other than COPD (e.g. asthma) * Cognitive reading impairment and/or difficulties to manage electronic devices precluding interaction with the smartphone and PDA, as judged by the investigator * Participating in or scheduled to start an outpatient rehabilitation program during the study. If the patient wishes to participate in pulmonary rehabilitation for any reason the patient can be enrolled in the study only at the end of rehabilitation

Design outcomes

Primary

MeasureTime frameDescription
Daily number of stepschanges from baseline to 3 monthsThe daily number of steps will be measured by the PROactive monitors (ActiGraph® and DynaPort®) at baseline (during the week prior to baseline visit) and at the end of the 3-month epoch (during the week prior to end visit).

Secondary

MeasureTime frameDescription
Proportion of patients showing an increase of physical activity by >20%changes from baseline to 3 monthsPhysical activity will be measured by the PROactive monitors (ActiGraph® and DynaPort®) at baseline (during the week prior to baseline visit) and at the end of the 3-month epoch (during the week prior to end visit).
6-minute walking testchanges from baseline to 3 months
isometric Quadriceps forcechanges from baseline to 3 months
COPD symptoms and health-related quality of lifechanges form baseline to 3 monthsCOPD symptoms and health-related quality of life will be measured by the CAT, CCQ, HADS and mMRC questionnaires
Time spent in at least moderate physical activitychanges from baseline to 3 monthsTime in at least moderate physical activity will be measured by the PROactive monitors (ActiGraph® and DynaPort®) at baseline (during the week prior to baseline visit) and at the end of the 3-month epoch (during the week prior to end visit).

Other

MeasureTime frameDescription
Compliance with the telecoaching programInformation gathered after 3 months of interventionCompliance of wearing the step counter and performing the tasks of the smartphone interface
Satisfaction with the telecoaching programInformation gathered after 3 months of interventionQuestionnaire and qualitative interview about the patients' experience
daily and clinic visit version of PROactive instrumentchanges from baseline to 3 months

Countries

Belgium, Greece, Netherlands, Switzerland, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026